IBD Archives - Buhlmann Diagnostics Corp

Tag: IBD

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al.  The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study.  Crohn's & Colitis 360 (2019).  DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”
Continue Reading

Four Years of Experience Using IBDoc

Benefits for Patients and Healthcare Staff of Routine IBDoc® Use Kathleen Sugrue, Advanced Nurse Practitioner at Mercy University Hospital, Cork (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article “Since introducing IBDoc® we get less calls on the helpline because patients can check themselves if they are concerned they are flaring.” “Patients
Continue Reading

Patient’s Perspective- One Year using IBDoc

Read a recent article written from the perspective of a long term Crohn's sufferer who shares his experience of managing the disease with the help of calprotectin self-testing. Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories. Highlight from this Perspective Article “It has reduced the “waiting time” for results down to hours instead of days or
Continue Reading

Biomarkers as predictors of flares in inflammatory bowel disease

BÜHLMANN sCAL ELISA: Lavric M et al.: Biomarkers as Predictors of Flares in Inflammatory Bowel Disease. Poster presented at final MIAMI Meeting (Translating Science into targets); 2016: April 13-15, Muenster (Germany). View Poster BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® Infliximab Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from this
Continue Reading